ObsEva (NASDAQ:OBSV) Now Covered by StockNews.com

Research analysts at StockNews.com assumed coverage on shares of ObsEva (NASDAQ:OBSV) in a research note issued to investors on Monday. The brokerage set a “hold” rating on the stock.

ObsEva Stock Down 15.5 %

Shares of ObsEva stock opened at $0.10 on Monday. The stock’s fifty day moving average is $0.06 and its 200-day moving average is $0.06. The firm has a market capitalization of $7.94 million, a PE ratio of -0.11 and a beta of 0.68. ObsEva has a 12-month low of $0.08 and a 12-month high of $2.14.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Bank of America Corp DE boosted its stake in shares of ObsEva by 54,142.2% during the 1st quarter. Bank of America Corp DE now owns 484,383 shares of the company’s stock worth $731,000 after acquiring an additional 483,490 shares in the last quarter. Two Sigma Investments LP bought a new stake in ObsEva during the 3rd quarter valued at approximately $25,000. Credit Suisse AG boosted its stake in ObsEva by 11.0% during the 4th quarter. Credit Suisse AG now owns 1,750,573 shares of the company’s stock valued at $255,000 after purchasing an additional 173,455 shares during the period. Millennium Management LLC acquired a new position in ObsEva in the 2nd quarter valued at approximately $192,000. Finally, XTX Topco Ltd raised its holdings in ObsEva by 33.9% in the 1st quarter. XTX Topco Ltd now owns 79,757 shares of the company’s stock valued at $120,000 after acquiring an additional 20,196 shares in the last quarter. 17.52% of the stock is owned by institutional investors and hedge funds.

ObsEva Company Profile

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.